Pharmaceutical Executive-05-01-2001

World News
Pharmaceutical Executive

May 01, 2001

London-Government and industry have agreed there should be no weakening of patent protection in the effort to speed access to medicines in the developing world.

Executive Profile
Pharmaceutical Executive

May 01, 2001

Grass never grew under her feet. She steadily rose to the top from the ranks of her industry. Now one of a handful of executive vice-presidents on the chairman's own management team, she co-directs the most important unit in the Pharmacia corporation, prescription pharmaceuticals, holding the title of president in that business.

Columns
Pharmaceutical Executive

May 01, 2001

Pharmaceutical executives should study their own scientists. They construct clever tools to explore convoluted phenomena. They are the true friends of complexity.

Features
Pharmaceutical Executive

May 01, 2001

Now that the pharma sales rep market has reached its saturation point, companies must focus on retention.

Features
Pharmaceutical Executive

May 01, 2001

Companies that fail to comply with regulatory guidelines make easy targets for investigators.

World News
Pharmaceutical Executive

May 01, 2001

A new task force will examine European pharma}s competitiveness, innovation, and commitment to public health. The "G10" is not, as it may sound, an enlarged grouping of the world}s leading industrialized countries. It}s actually far more important than that.

Features
Pharmaceutical Executive

May 01, 2001

Straddling the divide between drug discovery and drug delivery, Protarga doesn't fit neatly into any pharma category. It's not exactly a delivery technology company, because its products are patentable new entities that it plans to keep for itself. Nor is it purely biotech, because it works with chemical compounds. And in the end, president and CEO Nigel Webb expects Protarga to become a fully integrated pharma company-but only in the virtual sense.

Features
Pharmaceutical Executive

May 01, 2001

Companies Face Costly System Overhauls With New FDA Regulations

Washington Report
Pharmaceutical Executive

May 01, 2001

Concern that gene and stem-cell research could lead to human cloning has generated proposals for legislative bans, which could block promising research.